학술논문
Double Blind Controlled Study of Miroprofen in Acute Upper Respiratory Tract Infections Comparison with Ibuprofen / 急性上気道炎に対するMiroprofbnの薬効評価
Document Type
Journal Article
Author
Fumio YAMAZAKI; Fuyuhiko HIGASHI; Hiroshi NAKAGAWA; Hisao OHSUGA; Ippei FUJIMORI; Kohji OGIHARA; Kohji SEKI; Kohjiro SEKITA; Kuniyoshi IIZUKA; Masakatsu HAYAKAWA; Masataka KATSU; Michinori KOHNO; Mieko KAWAI; Sacchu SHIMADA; Satoshi SASAKI; Shinichi ENOMOTO; Shokichi YAMAZAKI; Shuji ITOH; Tatsuo NOGUCHI; Yasuo MATSUKI; Yoshihiko TAKEDA; 中川 浩; 伊藤 周治; 佐々木 智也; 勝 正孝; 大菅 久夫; 山崎 富美夫; 山崎 昭吉; 島田 佐仲; 早川 正勝; 東 冬彦; 松木 康夫; 榎本 新市; 河合 美枝子; 河野 通律; 竹田 義彦; 荻原 宏治; 藤森 一平; 野口 龍雄; 関 浩二; 関田 恒二郎; 飯塚 邦芳
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1982, 56(5):434
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
The efficacy and safety of miroprofen, a new non-steroidal analgesic/anti-inflammatory agent, were compared those of ibuprofen in 179 patients with acute upper respiratory infections by a double blind method. Patients were administered either miroprofen 150 mg t.i.d. or ibuprofen 300 mg t.i.d. for 4 days. The results were as follows;1. In final global improvement rating, clinical improvement was 89%(70/79) in miroprofen group and 83%(70/84) in ibuprofen group, showing no significant differences between two groups.2. In overall safety rating, adverse effects were 8%(7/83) in miroprofen group and 3%(3/86) in ibuprofen group, showing no significant differences between two groups.3. In improvement of severity rating on hoarse voice and pharynx redness on 2nd day, and headache on 4th day, miroprofen group was significantly superior to ibuprofen group (p<0.05).4. In global utility rating, usefulness was 81%(64/79) in miroprofen group and 81%(68/84) in ibuprofen group, showing no significant differences between two groups.